BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Apogenix 

Im Neuenheimer Feld 584

Heidelberg    69120  Germany
Phone: 49-0-6221-58608-0 Fax: 49-0-6221-58608-10


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Delivery





 Company News
Apogenix' APG101 Demonstrates Significant Prolongation Of Overall Survival In Biomarker-Positive Patients In Phase II Trial For The Treatment Of Recurrent Glioblastoma 1/13/2014 9:23:17 AM    More...
Apogenix To Present Phase II Results With APG101 For The Treatment Of Recurrent Glioblastoma At Biotech Showcase In San Francisco 1/7/2014 8:10:09 AM    More...
Apogenix' APG350 Effectively Induces Apoptosis Of Tumor Cells Via TRAIL Pathway Independent Of Fc-gamma Cross-Linking 12/5/2013 9:28:16 AM    More...
Apogenix Strengthens Patent Position for Apocept™ (APG101) in Europe and Canada 7/2/2013 10:00:36 AM    More...
Apogenix Receives FDA Orphan Drug Designation for Apocept™ to Treat Myelodysplastic Syndromes and Initiates Clinical Phase I Study 2/7/2013 10:18:04 AM    More...
Apogenix's Apocept™ for Glioblastoma Multiforme Named One of "Top 10 Projects to Watch" 11/6/2012 1:54:00 PM    More...
Apogenix: APG101 Exceeds Expectations With Controlled Phase II Clinical Trial in Treatment of Recurrent Glioblastoma 7/26/2012 10:01:36 AM    More...
Apogenix Receives Additional €2.3 Million BMBF Grant as Partner of the Biotech Cluster Rhine-Neckar 1/9/2012 2:40:12 PM    More...
Apogenix Raises €7.5 Million to Further Advance APG101 to Treat Glioblastoma and Other Tumors 1/5/2012 9:26:04 AM    More...
Apogenix Provides Update in the Ongoing Phase II Clinical Trial of APG101 to Treat Glioblastoma 1/24/2011 11:09:08 AM    More...
12

//-->